Evidence map›Paper›PMID 39048917›Full record

ArticleJournal of cellular and molecular medicine2024

PEDF and 34-mer peptide inhibit cardiac microvascular endothelial cell ferroptosis via Nrf2/HO-1 signalling in myocardial ischemia-reperfusion injury.

Peng Lu, Yuanpu Qi, Xiangyu Li, Cheng Zhang, Zhipeng Chen, Zihao Shen, Jingtian Liang, Hao Zhang, Yanliang Yuan

RetractedAbstract readRetracted Publication
In one paragraph

Article in Journal of cellular and molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Peng LuDepartment of Thoracic Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yuanpu QiDepartment of Cardiovascular Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Xiangyu LiDepartment of Cardiovascular Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Cheng ZhangDepartment of Thoracic Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Zhipeng ChenDepartment of Thoracic Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Zihao ShenDepartment of Cardiovascular Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Jingtian LiangDepartment of Thoracic Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Hao ZhangDepartment of Thoracic Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yanliang YuanDepartment of Thoracic Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.ORCID 0009-0007-0930-5491

Funding

Key Project of Affiliated Hospital of Xuzhou Medical University 2020KC012Social Development Projects of Medical and Health Programs in Xuzhou city KC21166
6 · The paper itself

Abstract

Myocardial ischemia-reperfusion injury (MIRI) represents a critical pathology in acute myocardial infarction (AMI), which is characterized by high mortality and morbidity. Cardiac microvascular dysfunction contributes to MIRI, potentially culminating in heart failure (HF). Pigment epithelium-derived factor (PEDF), which belongs to the non-inhibitory serpin family, exhibits several physiological effects, including anti-angiogenesis, anti-inflammatory and antioxidant properties. Our study aims to explore the impact of PEDF and its functional peptide 34-mer on both cardiac microvascular perfusion in MIRI rats and human cardiac microvascular endothelial cells (HCMECs) injury under hypoxia reoxygenation (HR). It has been shown that MIRI is accompanied by ferroptosis in HCMECs. Furthermore, we investigated the effect of PEDF and its 34-mer, particularly regarding the Nrf2/HO-1 signalling pathway. Our results demonstrated that PEDF 34-mer significantly ameliorated cardiac microvascular dysfunction following MIRI. Additionally, they exhibited a notable suppression of ferroptosis in HCMECs, and these effects were mediated through activation of Nrf2/HO-1 signalling. These findings highlight the therapeutic potential of PEDF and 34-mer in alleviating microvascular dysfunction and MIRI. By enhancing cardiac microvascular perfusion and mitigating endothelial ferroptosis, PEDF and its derivative peptide represent promising candidates for the treatment of AMI.

Indexed as

Endothelial CellsEye ProteinsFerroptosisMyocardial Reperfusion InjuryNerve Growth FactorsNF-E2-Related Factor 2SerpinsSignal TransductionAnimalsHeme Oxygenase-1HumansMaleMicrovesselsPeptidesPigment Epithelium-Derived FactorRatsEye ProteinsHeme Oxygenase-1Nerve Growth FactorsNfe2l2 protein, ratNF-E2-Related Factor 2PeptidesPigment Epithelium-Derived FactorSerpinsendotheliumferroptosismyocardial ischemia‐reperfusion injuryNrf2PEDF

Identifiers

PMID39048917
PMCPMC11269049

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.